Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 23;73(1):17.
doi: 10.1186/s43044-021-00140-1.

Egyptian practical guidance in lipid management 2020

Hesham Salah El Din Taha  1 , Hala Mahfouz Badran  2 , Hossam Kandil  3 , Nabil Farag  4 , Abbas Oraby  5 , Magdy El Sharkawy  4 , Khaled Shokry  6 , Fouad Fawzy  3 , Hossam Mahrous  3 , Juliette Bahgat  3 , Mina Samy  3 , Mirna Mamdouh Shaker  3
Affiliations
Review

Egyptian practical guidance in lipid management 2020

Hesham Salah El Din Taha et al. Egypt Heart J. .

Abstract

Background: Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events.

Main body: Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD.

Conclusion: The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.

Keywords: Atherosclerotic cardiovascular disease; Dyslipidemia; Practical guidance.

PubMed Disclaimer

Conflict of interest statement

Dr. Hala Mahfouz Badran is a co-author of this study. She has not handled this manuscript to avoid any conflict of interest. The rest of the authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Approach to lipid management
Fig. 2
Fig. 2
Treatment algorithm for LDL-C lowering. *Add PCSK9 inhibitor for secondary prevention in very-high-risk patients and for primary prevention in patients with FH and another major risk factor (very high risk). *Consider adding PCSK9 inhibitor for primary prevention patients at very high risk, but without FH
See this image and copyright information in PMC

References

    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal 41(1):111–188 - PubMed
    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 376(9753):1670–1681 - PMC - PubMed
    1. Michos ED, McEvoy JW, Blumenthal RS (2019) Lipid management for the prevention of atherosclerotic cardiovascular disease. The New England Journal of Medicine 381(16):1557–1567 - PubMed
    1. Reda A, Abdel-Rehim AA, Etman A, Afifi OSA (2014) Centralized pan-Middle East Survey on the under-treatment of hypercholesterolemia: results from the CEPHEUS study in Egypt. Cardiol Ther. 3(1–2):27–40 - PMC - PubMed
    1. Farag ES, Reda A, Farag N, Salama S, Elbahry A, Sanad O et al (2017) The Egyptian cardiovascular risk factors project, phase (II) results: a multicenter observational study of the pattern of risk factor profile in Egyptian patients with acute coronary syndrome. Atherosclerosis. 263:e159